BACKGROUND: Preliminary studies suggest that physical exercise interventions can improve physical fitness, fatigue and quality of life in cancer patients after completion of chemotherapy. Additional research is needed to rigorously test the effects of exercise programmes among cancer patients and to determine optimal training intensity accordingly. The present paper presents the design of a randomized controlled trial evaluating the effectiveness and cost-effectiveness of a high intensity exercise programme compared to a low-to-moderate intensity exercise programme and a waiting list control group on physical fitness and fatigue as primary outcomes. METHODS: After baseline measurements, cancer patients who completed chemotherapy are randomly assigned to either a 12-week high intensity exercise programme or a low-to-moderate intensity exercise programme. Next, patients from both groups are randomly assigned to immediate training or a waiting list (i.e. waiting list control group). After 12 weeks, patients of the waiting list control group start with the exercise programme they have been allocated to.Both interventions consist of equal bouts of resistance and endurance interval exercises with the same frequency and duration, but differ in training intensity. Additionally, patients of both exercise programmes are counselled to improve compliance and achieve and maintain an active lifestyle, tailored to their individual preferences and capabilities.Measurements will be performed at baseline (t = 0), 12 weeks after randomization (t = 1), and 64 weeks after randomization (t = 2). The primary outcome measures are cardiorespiratory fitness and muscle strength assessed by means of objective performance indicators, and self-reported fatigue. Secondary outcome measures include health-related quality of life, self-reported physical activity, daily functioning, body composition, mood and sleep disturbances, and return to work. In addition, compliance and satisfaction with the interventions will be evaluated. Potential moderation by pre- and post-illness lifestyle, health and exercise-related attitudes, beliefs and motivation will also be assessed. Finally, the cost-effectiveness of both exercise interventions will be evaluated. DISCUSSION: This randomized controlled trial will be a rigorous test of effects of exercise programmes for cancer patients afterchemotherapy, aiming to contribute to evidence-based practice in cancer rehabilitation programmes. TRIAL REGISTRATION: This study is registered at the Netherlands Trial Register (NTR2153).
RCT Entities:
BACKGROUND: Preliminary studies suggest that physical exercise interventions can improve physical fitness, fatigue and quality of life in cancerpatients after completion of chemotherapy. Additional research is needed to rigorously test the effects of exercise programmes among cancerpatients and to determine optimal training intensity accordingly. The present paper presents the design of a randomized controlled trial evaluating the effectiveness and cost-effectiveness of a high intensity exercise programme compared to a low-to-moderate intensity exercise programme and a waiting list control group on physical fitness and fatigue as primary outcomes. METHODS: After baseline measurements, cancerpatients who completed chemotherapy are randomly assigned to either a 12-week high intensity exercise programme or a low-to-moderate intensity exercise programme. Next, patients from both groups are randomly assigned to immediate training or a waiting list (i.e. waiting list control group). After 12 weeks, patients of the waiting list control group start with the exercise programme they have been allocated to.Both interventions consist of equal bouts of resistance and endurance interval exercises with the same frequency and duration, but differ in training intensity. Additionally, patients of both exercise programmes are counselled to improve compliance and achieve and maintain an active lifestyle, tailored to their individual preferences and capabilities.Measurements will be performed at baseline (t = 0), 12 weeks after randomization (t = 1), and 64 weeks after randomization (t = 2). The primary outcome measures are cardiorespiratory fitness and muscle strength assessed by means of objective performance indicators, and self-reported fatigue. Secondary outcome measures include health-related quality of life, self-reported physical activity, daily functioning, body composition, mood and sleep disturbances, and return to work. In addition, compliance and satisfaction with the interventions will be evaluated. Potential moderation by pre- and post-illness lifestyle, health and exercise-related attitudes, beliefs and motivation will also be assessed. Finally, the cost-effectiveness of both exercise interventions will be evaluated. DISCUSSION: This randomized controlled trial will be a rigorous test of effects of exercise programmes for cancerpatients after chemotherapy, aiming to contribute to evidence-based practice in cancer rehabilitation programmes. TRIAL REGISTRATION: This study is registered at the Netherlands Trial Register (NTR2153).
Authors: Mieke Cardol; Anita Beelen; Geertrudis A van den Bos; Bareld A de Jong; Imelda J de Groot; Rob J de Haan Journal: Arch Phys Med Rehabil Date: 2002-11 Impact factor: 3.966
Authors: G A Curt; W Breitbart; D Cella; J E Groopman; S J Horning; L M Itri; D H Johnson; C Miaskowski; S L Scherr; R K Portenoy; N J Vogelzang Journal: Oncologist Date: 2000
Authors: Roanne J Segal; Robert D Reid; Kerry S Courneya; Shawn C Malone; Matthew B Parliament; Chris G Scott; Peter M Venner; H Arthur Quinney; Lee W Jones; Monika E Slovinec D'Angelo; George A Wells Journal: J Clin Oncol Date: 2003-05-01 Impact factor: 44.544
Authors: Anne M May; Ellen Van Weert; Irene Korstjens; Josette E H M Hoekstra-Weebers; Cees P Van Der Schans; Maria L Zonderland; Ilse Mesters; Bart Van Den Borne; Wynan D J G Ros Journal: Acta Oncol Date: 2008 Impact factor: 4.089
Authors: Ellen van Weert; Josette E H M Hoekstra-Weebers; Anne M May; Irene Korstjens; Wynand J G Ros; Cees P van der Schans Journal: Patient Educ Couns Date: 2008-02-05
Authors: F Hausmann; V V Iversen; M Kristoffersen; H Gundersen; E Johannsson; M Vika Journal: Support Care Cancer Date: 2018-04-14 Impact factor: 3.603
Authors: Shiraz I Mishra; Roberta W Scherer; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu; Carolyn C Gotay; Claire Snyder Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Shiraz I Mishra; Roberta W Scherer; Claire Snyder; Paula M Geigle; Debra R Berlanstein; Ozlem Topaloglu Journal: Cochrane Database Syst Rev Date: 2012-08-15
Authors: Mai J M Chinapaw; Laurien M Buffart; Willem van Mechelen; Goof Schep; Neil K Aaronson; Wim H van Harten; Martijn M Stuiver; Marie José Kersten; Frans Nollet; Gertjan J L Kaspers; Eline van Dulmen-den Broeder; Jaap Huisman; Tim Takken; Maurits van Tulder; Johannes Brug Journal: Int J Behav Med Date: 2012-06
Authors: Caroline S Kampshoff; Mai J M Chinapaw; Johannes Brug; Jos W R Twisk; Goof Schep; Marten R Nijziel; Willem van Mechelen; Laurien M Buffart Journal: BMC Med Date: 2015-10-29 Impact factor: 8.775
Authors: Charlotte IJsbrandy; Petronella B Ottevanger; Wim G Groen; Winald R Gerritsen; Wim H van Harten; Rosella P M G Hermens Journal: Implement Sci Date: 2015-09-07 Impact factor: 7.327
Authors: M Touillaud; A-M Foucaut; S E Berthouze; E Reynes; A-S Kempf-Lépine; J Carretier; D Pérol; S Guillemaut; S Chabaud; V Bourne-Branchu; L Perrier; O Trédan; B Fervers; P Bachmann Journal: BMJ Open Date: 2013-10-28 Impact factor: 2.692
Authors: Caroline S Kampshoff; Fiona Stacey; Camille E Short; Willem van Mechelen; Mai Jm Chinapaw; Johannes Brug; Ronald Plotnikoff; Erica L James; Laurien M Buffart Journal: Support Care Cancer Date: 2016-03-12 Impact factor: 3.603
Authors: Caroline S Kampshoff; Willem van Mechelen; Goof Schep; Marten R Nijziel; Lenja Witlox; Lisa Bosman; Mai J M Chinapaw; Johannes Brug; Laurien M Buffart Journal: Int J Behav Nutr Phys Act Date: 2016-09-09 Impact factor: 6.457